V. Kakkar

发表

Investigation of the Interaction of Blood Platelets with the Coagulation System at the Site of Plug Formation In Vivo in Man - Effect of Low-Dose Aspirin

J. Westwick, M. Scully, P. Kyrle, 1987, Thrombosis and Haemostasis.

Thrombolytic therapy.

M. Scully, V. Kakkar, 1968, British medical bulletin.

Identification of heparin cofactor II as the principal plasma cofactor for the antithrombin activity of pentosan polysulphate (SP54).

M. Scully, V. Kakkar, 1984, Thrombosis research.

Structural features of fibrinogen associated with binding to chelated zinc.

M. Scully, V. Kakkar, 1982, Biochimica et biophysica acta.

Non-specific influence of chemical modification upon the properties of antithrombin III:modification of carboxyl groups.

M. Scully, V. Kakkar, C. Goodwin, 1992, Thrombosis research.

Methods for semi micro or automated determination of thrombin, antithrombin, and heparin cofactor using he substrate, H-D-Phe-Pip-Arg-p-nitroanilide-2HCl.

M. Scully, V. Kakkar, 1977, Clinica chimica acta; international journal of clinical chemistry.

Tissue-selective expression of dominant-negative proteins for the regulation of vascular smooth muscle cell proliferation

M. Keogh, D. Chen, N. Lemoine, 1999, Gene Therapy.

Influence of Intrinsic and Extrinsic Plasminogen upon the Lysis of Thrombi In Vitro

M. Scully, V. Kakkar, N. Nishino, 1991, Thrombosis and Haemostasis.

High efficiency reporter gene transfection of vascular tissue in vitro and in vivo using a cationic lipid–DNA complex

M. Keogh, D. Chen, N. Lemoine, 1997, Gene Therapy.

Extended prophylaxis with bemiparin for the prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study

P. Prandoni, V. Kakkar, V. Kakkar, 2010, Journal of thrombosis and haemostasis : JTH.

Mechanisms of Stimulus—Response Coupling in Platelets

J. Westwick, M. Scully, D. Macintyre, 1985, Advances in Experimental Medicine and Biology.

Efficacy of low-dose heparin prophylaxis.

V. Kakkar, 1975, Current therapeutic research, clinical and experimental.

Hereditary Antithrombin III Deficiency in an English Family

M. Scully, V. Kakkar, H. D. Haas, 1981, British journal of haematology.

Use of Low Molecular Weight Heparin in Pregnancy

K. Nicolaides, C. Kanthou, V. Kakkar, 1992, Thrombosis and Haemostasis.

Low-molecular-weight heparin and prevention of postoperative deep vein thrombosis.

J. Westwick, M. Scully, V. Kakkar, 1982, British medical journal.

Late-onset homozygous protein C deficiency

M. Scully, E. Melissari, V. Kakkar, 1991, The Lancet.

An Experimental Model for the Study of Venous Thrombosis in Vivo

M. Scully, P. Gaffney, T. K. Day, 1974, Thrombosis and Haemostasis.

Uses of Low Molecular Weight Heparins

V. Kakkar, D. Gerrard, 1995 .

Effect of low molecular weight heparin on intimal hyperplasia

V. Kakkar, V. Kakkar, N. Wilson, 1991, The British journal of surgery.

Do prostacyclin and thromboxane play a role in endotoxic shock?

J. Westwick, M. Scully, J. Zahavi, 1981, The British journal of surgery.

A cyclic peptide analogue of loop III of PDGF‐BB causes apoptosis in human fibroblasts

M. Scully, V. Kakkar, D. Brennand, 1997, FEBS letters.

Annexin V as a probe of the contribution of anionic phospholipids to the procoagulant activity of tumour cell surfaces.

M. Scully, R. Donato, M. Sugimura, 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

Fibrin subunits in venous and arterial thromboembolism.

M. Scully, P. Gaffney, V. Kakkar, 1976, Cardiovascular research.

Congenital thrombophilia among patients with venous thromboembolism

S. Das, E. Melissari, V. Kakkar, 1992, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

The effect of low molecular weight heparin on intimal hyperplasia in vein grafts.

V. Kakkar, N. Wilson, J. R. Salisbury, 1994, European journal of vascular surgery.

Mercury compounds induce a rapid increase in procoagulant activity of monocyte‐like U937 cells

M. Scully, V. Kakkar, H. Kaneko, 1994, British journal of haematology.

PREVENTION OF FATAL POSTOPERATIVE PULMONARY EMBOLISM BY LOW-DOSE HEPARIN

J. Torhorst, V. Kakkar, J. Thirlwell, 1977, The Lancet.

Binding of fibrinogen fragment D to chelated zinc: localization of a possible binding site.

M. Scully, V. Kakkar, 1983, Thrombosis Research.

The behavior of isotope labelled blood proteins in thrombosis.

M. Scully, V. Kakkar, C. Strachan, 1974, Thrombosis Research.

Method for the determination of plasminogen which discriminates between native and degraded plasminogen.

M. Scully, V. Kakkar, 1978, Thrombosis research.

Intra-operative antithrombotic therapy with low molecular weight heparin in aortic surgery. How should heparin be administered?

N. Standfield, E. Melissari, V. Kakkar, 1991, European journal of vascular surgery.

Plasma levels of tissue factor pathway inhibitor in thrombophilic patients.

M. Scully, E. Melissari, V. Kakkar, 1993, Thrombosis research.

A molecular model of the serine protease domain of activated protein C: application to the study of missense mutations causing protein C deficiency

A. Wacey, S. Pemberton, E. Tuddenham, 1993, British journal of haematology.

The molecular genetic analysis of haemophilia A; characterization of six partial deletions in the factor VIII gene

D. Cooper, M. Krawczak, D. Whitmore, 1990, Human Genetics.

A cyclic peptide analogue of the loop III region of platelet-derived growth factor-BB is a synthetic antigen for the native protein.

V. Kakkar, J. Deadman, D. Brennand, 1999, The journal of peptide research : official journal of the American Peptide Society.

Design of a muscle cell-specific expression vector utilising human vascular smooth muscle α-actin regulatory elements

M. Keogh, D. Chen, N. Lemoine, 1999, Gene Therapy.

The diagnosis of deep vein thrombosis using the 125 I fibrinogen test.

V. Kakkar, 1972, Archives of surgery.

The detection of venous thrombosis of the legs using 125I‐labelled fibrinogen

V. Kakkar, C. Flanc, M. B. Clarke, 1968, The British journal of surgery.

Low‐dose heparin to low molecular weight heparin prophylaxis: in pursuit of excellence – a personal perspective

V. Kakkar, V. Kakkar, 2005, Journal of thrombosis and haemostasis : JTH.

Heparin: Chemistry and clinical usage

V. Kakkar, D. Thomas, 1976 .

Automated Control of Coumarin Therapy by Chromogenic Factor X Assay

M. Scully, I. Macgregor, R. Mibashan, 1979, Thrombosis and Haemostasis.

CONGENITAL SEVERE PROTEIN C DEFICIENCY IN ADULTS

E. Melissari, V. Kakkar, V. Kakkar, 1989, Thrombosis and Haemostasis.

Antithrombin‐TRI (Ala 382 to Thr) causing severe thromboembolic tendency undergoes the S‐to‐R transition and is associated with a plasma‐inactive high‐molecular‐weight complex of aggregated antithrombin

H. Morris, M. Panico, F. Zappacosta, 1995, British journal of haematology.

Duodenal obstruction due to an anomalous portal vein.

V. Kakkar, A. Tompkin, 1968, Postgraduate medical journal.

Antithrombotic therapy in patients with chronic heart failure: rationale, clinical evidence and practical implications

V. Kakkar, O. Dotsenko, V. Kakkar, 2007, Journal of thrombosis and haemostasis : JTH.

Inhibition of fibrinolytic activity by hyaluronan and its alcohol ester derivatives.

M. Scully, M. O'regan, V. Kakkar, 1995, Thrombosis research.

Measurement of degraded forms of plasminogen in human plasma.

M. Scully, V. Kakkar, 1980, Thrombosis research.

An Acquired Inhibitor To Coagulation Factor II

V. Ellis, G. Savidge, V. Kakkar, 1967, Thrombosis and Haemostasis.

GENERATION OF REACTIVE OXYGEN METABOLITES BY PHAGOCYTOSING ENDOTHELIAL CELLS: REGULATORY ROLE OF THE GLYCOCALYX

P. Görög, V. Kakkar, J. Pearson, 1987, Thrombosis and Haemostasis.

Septic arthritis of the knee: complication of intra-arterial thrombolytic therapy.

V. Kakkar, N. Wilson, A. Patel, 1993, European journal of vascular surgery.

A Chromogenic Semi-Micro Method for the Determination of Factor Xa, Factor Xa Inhibitor and Mini-Dose Heparin Levels

M. Scully, V. Kakkar, 1977, Thrombosis and Haemostasis.

Zinc Chelate Chromatography Of Fibrinogen

M. Scully, V. Kakkar, 1981, Thrombosis and Haemostasis.

Improved carrier detection of haemophilia A using novel RFLPs at the DXS115 (767) locus

D. Cooper, P. Jedlicka, D. Millar, 1990, Human Genetics.

A HEPARIN ANALOGUE WITH SPECIFIC ACTION ON ANTITHROMBIN III

V. Kakkar, D. Lane, D. Thomas, 1977, The Lancet.

Thrombin receptor activating peptide does not stimulate platelet procoagulant activity.

M. Scully, J. Deadman, C. Wheeler-Jones, 1994, Biochemical and Biophysical Research Communications - BBRC.

Potentiation by Lys-Plasminogen of Clot Lysis by Single or Two Chain Urokinase-Type Plasminogen Activator or Tissue-Type Plasminogen Activator

M. Scully, V. Kakkar, V. Ellis, 1989, Thrombosis and Haemostasis.

Biochemical Comparison of Intermittent Streptokinase and Intermittent Streptokinase and Plasminogen Therapy

P. G. Bentley, G. Barlow, N. Jones, 1979, Thrombosis and Haemostasis.

Modulation of endothelin receptor expression in human vascular smooth muscle cells by interleukin‐1β

P. Newman, V. Kakkar, S. Kanse, 1995, FEBS letters.

A comparative study of low doses of heparin and a heparin analogue in the prevention of postoperative deep vein thrombosis.

P. G. Bentley, M. Scully, V. Kakkar, 1978, Thrombosis Research.

Fibrinogen Degradation in Normal and Fibrinolytic Plasma

M. Scully, V. Kakkar, 1975, Thrombosis and Haemostasis.

The effect of divalent metal cations on the inhibition of human coagulation factor Xa by plasma proteinase inhibitors.

M. Scully, V. Ellis, V. Kakkar, 1983, Biochimica et biophysica acta.

Intermittent Plasminogen-Streptokinase Treatment of Deep Vein Thrombosis

M. Scully, D. Lane, D. Thomas, 1977, Thrombosis and Haemostasis.

Factors involved in the detection of pulmonary emboli by labelling techniques.

M. Scully, M. B. Clarke, V. Kakkar, 1976, The British journal of radiology.

Properties of Thrombolytic Agents in Vitro Using a Perfusion Circuit Attaining Shear Stress at Physiological Levels

M. Scully, M. Rampling, V. Kakkar, 1990, Thrombosis and Haemostasis.

Bound plasminogen is rate-limiting for cell-surface-mediated activation of plasminogen by urokinase.

M. Scully, S. Namiranian, V. Kakkar, 1995, The Biochemical journal.